Prospektive Versorgungsforschungsstudie zur Therapie mit Immunglobulinen (SIGNS)
暂无分享,去创建一个
W. Kirch | U. Baumann | D. Pittrow | M. Borte | R. Gold | M. Stangel | M. Reiser | D. Huscher | M. Hensel | M. Fasshauer
[1] R. Gold,et al. Einsatz intravenöser Immunglobuline in der Neurologie , 2010, Der Nervenarzt.
[2] H. Bueno,et al. The role of cardiac registries in evidence-based medicine. , 2010, European heart journal.
[3] S. Jacob,et al. Current Proposed Mechanisms of Action of Intravenous Immunoglobulins in Inflammatory Neuropathies , 2009, Current neuropharmacology.
[4] E. Neugebauer,et al. Die Erfassung von Lebensqualität in der Versorgungsforschung - konzeptuelle, methodische und strukturelle Voraussetzungen. , 2009 .
[5] J. Jakobsen,et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single‐blinded cross‐over trial , 2009, European journal of neurology.
[6] W. Köbberling,et al. Zu Viviane Knerr et al. Die ESID-Online-Datenbank für primäre Immundefekte , 2008, Medizinische Klinik.
[7] B. Grimbacher,et al. [The ESID Online Database for primary immunodeficiencies. First analyses with regard to Germany and Europe]. , 2008, Medizinische Klinik.
[8] N. Gilhus,et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases , 2008, European journal of neurology.
[9] Shigeaki Nonoyama,et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. , 2007, The Journal of allergy and clinical immunology.
[10] M. Bullinger,et al. [Methodological challenges and potentials of health-related quality of life evaluation in children with chronic health conditions under medical health care]. , 2007, Medizinische Klinik.
[11] U. S. Department of Health and Human Services FDA Cen Research,et al. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.
[12] N. Leidy,et al. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] J S Alpert,et al. Are data from clinical registries of any value? , 2000, European heart journal.
[14] L. Hammarström,et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs , 1995, The Lancet.
[15] M. Bullinger,et al. Generic Health-Related Quality-of-Life Assessment in Children and Adolescents , 2012, PharmacoEconomics.
[16] M. Koller,et al. [Assessment of quality of life in health services research - conceptual, methodological and structural prerequisites]. , 2009, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).
[17] L. Notarangelo,et al. Primary immunodeficiency diseases , 2008 .